SANTA CLARA, Calif.--(BUSINESS WIRE)-- Curie AI, a tech-enabled respiratory care company that has developed cutting-edge technology for passive respiratory patient monitoring, today announced the closing of a seed round from investors that include ResMed, Factory and SeedToB.

“We are thrilled to have this support from our investors,” says Navya Davuluri, Curie AI’s CEO and Co-Founder. “This investment round will allow us to scale our commitment to this industry beyond just our monitoring technology into a complete virtual care platform purpose-built for managing respiratory conditions.”

Curie AI’s technology has seen early success with organizations such as the Allergy & Asthma Network (AAN) and the San Carlos Apache Healthcare Corporation (SCAHC). In these trials, the passive monitoring achieved a 98% adherence and the resulting insights led to a 60% reduction in rescue inhaler use and over 80% reduction in ER visits and hospitalization.

The Curie AI platform is deployed on a simple tablet that sits at the patient’s bedside in their home. The technology uses a proprietary set of over one million hours of respiratory audio biomarkers to scan and listen for symptoms from the patient such as shortness of breath, productive cough vs. dry cough etc., and delivers actionable insights allowing clinicians to have regular and objective feedback on the health of their patient.

“Curie AI’s technology is poised to be a market leader in the respiratory disease management space because of its ease of use and powerful AI models and insights,” said Andrew Jacques, CEO of Factory. “The combination of this technology and clinical protocols that Curie AI has put together will be game changing for the respiratory industry.”

Curie AI is already deploying its solution across select healthcare organizations across US and will expand its footprint with leading health systems and independent provider organizations throughout 2022.

About Curie AI

Curie AI is a StartX-backed tech-enabled respiratory care provider that makes it easy to provide virtual personalized disease management and life-saving care using patented AI technology, actionable insights, and a specialized clinical team. Our passive monitoring technology allows for automatic adherence resulting in early detection by our smart care team and a reduction in adverse events — saving costs and improving quality of life. Learn more at www.curieai.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005028/en/